Background In MONALEESA-2, ribociclib plus letrozole showed improved progression-free
survival compared with letrozole alone as first-line treatment for postmenopausal patients …

Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …

Purpose National Cancer Institute of Canada Clinical Trials Group Study BR. 21 established
erlotinib as a standard of care in patients with non–small-cell lung cancer (NSCLC) after …

Purpose: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant
progression-free survival and overall survival (OS) benefit in the phase III MONALEESA-7 trial of …

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to
immunotherapy. BR.36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of molecular …

Approximately 30 to 40% of patients with advanced lung cancer will develop bone metastases
in the course of their disease, resulting in a significant negative impact on both morbidity …

Background: Some non-small-cell lung cancer (NSCLC) surgical series have indicated that
the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We …

Introduction Non-small cell lung cancer (NSCLC) is the leading global cause of cancer death.
While bone metastases (BM) commonly cause morbidity, bone-targeted agent (BTA) use is …

Lung cancer is a highly heterogeneous disease often driven by well-characterized driver
mutations. Although the best studied are common alterations in the epidermal growth factor …

Background Bone metastases (BM) are common in NSCLC patients. Despite some potential
positive effects of bone-targeted therapies, their use in NSCLC is infrequent, which may …